[{"id":"b6d223e7-2b21-4043-9c4a-6bf6dab3f345","acronym":"SABINA","url":"https://clinicaltrials.gov/study/NCT05810870","created_at":"2023-04-12T14:03:37.667Z","updated_at":"2024-07-02T16:34:59.522Z","phase":"Phase 2","brief_title":"PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin","source_id_and_acronym":"NCT05810870 - SABINA","lead_sponsor":"MedSIR","biomarkers":" PIK3CA • PTEN","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • izorlisib (MEN1611)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 05/24/2023","start_date":" 05/24/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-06-03"},{"id":"8e05bd45-d1ec-430f-855b-a80c51085726","acronym":"B-PRECISE-01","url":"https://clinicaltrials.gov/study/NCT03767335","created_at":"2021-01-17T17:24:54.779Z","updated_at":"2024-07-02T16:35:03.228Z","phase":"Phase 1","brief_title":"MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer","source_id_and_acronym":"NCT03767335 - B-PRECISE-01","lead_sponsor":"Menarini Group","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • fulvestrant • izorlisib (MEN1611)"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 07/19/2018","start_date":" 07/19/2018","primary_txt":" Primary completion: 01/22/2024","primary_completion_date":" 01/22/2024","study_txt":" Completion: 02/23/2024","study_completion_date":" 02/23/2024","last_update_posted":"2024-05-16"},{"id":"d4b81b99-d243-4c1f-add1-f65829f75ba3","acronym":"C-PRECISE-01","url":"https://clinicaltrials.gov/study/NCT04495621","created_at":"2021-01-18T21:35:30.672Z","updated_at":"2024-07-02T16:35:03.454Z","phase":"Phase 1/2","brief_title":"MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)","source_id_and_acronym":"NCT04495621 - C-PRECISE-01","lead_sponsor":"Menarini Group","biomarkers":" KRAS • BRAF • PIK3CA • RAS","pipe":" | ","alterations":" BRAF mutation • PIK3CA mutation • BRAF wild-type","tags":["KRAS • BRAF • PIK3CA • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • PIK3CA mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • izorlisib (MEN1611)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 07/20/2020","start_date":" 07/20/2020","primary_txt":" Primary completion: 01/12/2024","primary_completion_date":" 01/12/2024","study_txt":" Completion: 02/27/2024","study_completion_date":" 02/27/2024","last_update_posted":"2024-05-15"}]